OSOlha Volodymyrivna Slobodianiuk

Olha Volodymyrivna Slobodianiuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olha Volodymyrivna Slobodianiuk has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • O. M. Bilyi

    State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine; V.N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine

    4 shared publications
  • Mykola Krasnoselskyi

    Державна установа «Інститут медичної радіології та онкології ім. С.П. Григор’єва Національної академії медичних наук України», Харків, Україна

    2 shared publications
  • Alla Mykolaivna Nasonova

    State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

    1 shared publication
  • I. V. Lepekha

    Державна установа «Інститут медичної радіології та онкології ім. С.П. Григор'єва Національної академії медичних наук України» Харків Україна

    1 shared publication
  • I.M. Teslenko

    State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

    1 shared publication
  • Kateryna Volodymyrivna Nemaltsova

    V. N. Karazin Kharkiv National University of Ministry of Education and Science of Ukraine, Kharkiv, Ukraine

    1 shared publication

Latest Publications

  • Open Access

    Immunotherapy – a new stage in the treatment of locally advanced cervical cancer

    by Vladyslav Serhiyovych Sukhin, Kateryna Volodymyrivna Nemaltsova, Alla Mykolaivna Nasonova, Olha Volodymyrivna Slobodianiuk, Olena Mykolayivna Sukhina

    Background. Cervical cancer ranks the fifth place in cancer incidence structure among women in the world and second place in the structure of cancer incidence among women of reproductive age in Ukraine. Despite screening programs, about 25% of cases in Ukraine are diagnosed at advanced (III–IV) stage, which critically reduces five-year survival rate (from 91% in early stages to 17–19% in case of metastatic disease ) in the whole population. Purpose – to analyze the evolution of treatment methods for locally advanced cervical cancer, based on large-scale clinical trials and to highlight the effectiveness of integrating immunotherapy into modern treatment guidelines for LACC patients. Materials and Methods. There was conducted a systematic review of full-text publications, cited by PubMed and Europe PMC databases. Scientific analysis was supplemented with a description of our own clinical observation of a patient with a locally advanced cervical cancer, who received treatment with immunotherapy. Results. The transformation of treatment standards from radiation therapy alone to modern concomitant chemoradiotherapy was studied. The key phase III clinical trials, that defined modern standards for cervical cancer therapy were analyzed. It was established that GOG 120 study confirmed as the «gold standard» the combined chemoradiotherapy based on cisplatin. It was proven that the addition of bevacizumab (GOG 240) and the introduction of pembrolizumab immunotherapy (KEYNOTE-826) has significantly improved overall survival rates in metastatic forms. Particular attention is paid to the results of GOG 3047 study, which demonstrated that the addition of pembrolizumab to standard therapy reduces the risk of death by 33% in patients with locally advanced disease. The effectiveness of antibody-drug conjugates (Tizotumab vedotin) is also highlighted, which has opened up new opportunities for the treatment of recurrent cervical cancer. Conclusions. Results from clinical trials demonstrate that combining of anti-PD-1 therapy (pembrolizumab) with chemoradiotherapy in high-risk locally advanced cervical cancer patients provides statistically and clinically significant improvements in progression-free and overall survival. This treatment strategy represents a promising new standard of care for the above-mentioned group of patients.

  • Serum vascular endothelial growth factor levels and tumor molecular marker expression in patients with secondary-edematous breast cancer during treatment dynamics

    by O.M. Bilyі, N.A. Mitrіaіeva, L.V. Grebinyk, O.V. Slobodianiuk, S.O. Pylypenko

    Background. Secondary-edematous breast cancer is characterized by high aggressiveness and a lack of clear prognostic markers. Studying the role of Vascular Endothelial Growth Factor in relation to the expression of steroid hormone receptors, HER2/neu, and Ki-67 in tumors allows assessment of the tumorʼs aggressiveness and helps optimize treatment. Purpose – to investigate the relationship between serum Vascular Endothelial Growth Factor levels and the expression of molecular markers in tumors of secondary- edematous breast cancer patients during treatment dynamics, and to determine the prognostic factors of the disease course. Materials and Methods. Fifty-four Secondary Estrogen Receptor–Positive Breast Cancer patients with T4bN0-2M0 were examined and underwent comprehensive treatment: neoadjuvant polychemotherapy (AC×4-D×4 or AC×4-P×12), surgical intervention, and radiation therapy. Vascular Endothelial Growth Factor levels in serum were determined before and after treatment by enzyme-linked immunosorbent assay, and ER, PR, HER2/ neu, and Ki-67 expression in the tumor was determined immunohistochemically. Results. A significantly increased serum Vascular Endothelial Growth Factor level was found in secondary-edematous breast cancer patients compared to the control group. Elevated Vascular Endothelial Growth Factor correlated with a higher tumor grade, Ki-67 overexpression, negative steroid hormone receptor status, and Human Epidermal Growth Factor Receptor 2. After treatment, Vascular Endothelial Growth Factor levels decreased in patients with tumor regression, while in those with disease progression, VEGF remained consistently high. Conclusions. Serum Vascular Endothelial Growth Factor is an important marker of tumor aggressiveness and treatment response in secondary-edematous breast cancer. Monitoring Vascular Endothelial Growth Factor alongside tumor molecular markers can be used to predict disease progression and select treatment strategies.


  • Open Access

    Addressing key clinical issues during neoadjuvant polychemotherapy in patients with secondary-edematous breast cancer using magnetic resonance imaging

    by O.M. Bilуi, S.M. Palchyk, М.в. Красносельський, O.V. Slobodіanіuk

    Background. Monitoring tumor regression and perifocal edema using Magnetic Resonance Imaging (MRI) is becoming crucial in NeoAdjuvant Chemotherapy (NAC) for Inflammatory Breast Cancer (IBC), as conventional imaging methods have low reliability for assessing treatment response. Aim. To investigate the role of MRI in addressing key clinical issues during NAC in patients with IBC. The study aimed to determine the effectiveness of MRI in dynamically assessing the primary tumor and perifocal edema zone, which is essential for adjusting treatment strategies and predicting therapy response. Materials and Methods. The study included 36 patients with IBC at stage T4bN0–3M0. MRI was performed before treatment and after NAC to evaluate tumor regression and perifocal edema. Statistical analysis was conducted using Statistica 14.0 (TIBCO Software Inc., USA) with non-parametric methods for small samples. Data are presented as Me (median). Results were compared between groups using the Wilcoxon test. Differences were considered statistically significant at p<0.05. Research Ethics. The study was conducted in accordance with the ethical standards of the World Medical Association's Declaration of Helsinki (1964–2024), European Community Directive 86/609 on the participation of humans in biomedical research, and Order No.690 of the Ministry of Health of Ukraine dated September 23, 2009. Informed consent was obtained from all participants. Results. Reduction of the edema zone on MRI after adding ranselex to NAC was significantly greater than without it (78.3% vs. 67.7%; p<0.05). Regression of the primary tumor in the ranselex group was also significantly higher (69.2% vs. 57.5%; p<0.05). Primary tumor regression was statistically significantly greater in the combination therapy group (69.2% vs. 57.5%; p<0.05). Dynamic contrast-enhanced MRI was effective in detecting residual tumor tissue after NAC, with a sensitivity of 92.8%, specificity of 82.0%, and overall accuracy of 85.6%. Conclusions. The feasibility of using MRI as an effective tool for monitoring tumor regression and perifocal edema in IBC patients during NAC and for surgical planning has been confirmed. This enables timely adjustment of treatment regimens and increases the likelihood of treatment response. Keywords: oncology, MRI, tumor regression, perifocal edema.


  • Open Access

    Giant retroperitoneal liposarcoma with spread to the upper third of the left thigh

    by М.в. Красносельський, O.M. Bilyy, R.A. Pidlisnyy, Ye.YU. Masalitina, O.V. Slobodianiuk, Є.ю. Масалітіна

    Background. Large tumors, such as giant liposarcoma, are a challenge for modern medicine because of difficulty of treatment and possible impact on functions of the adjacent tissues and organs. The review of this clinical case may help develop new strategies and approaches to treatment of similar pathologies. Purpose. Review of the clinical case has a goal to educate medical specialists and students by helping to expand their understanding of rare oncologic diseases and to prove high effectiveness of surgery in locally advanced types of retroperitoneal liposarcomas using the clinical case as an example. Materials and methods. Female patient C., 56 years old, sought for medical help in the clinical unit of State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine» in June 2021. The following diagnosis was established: retroperitoneal liposarcoma with spread to the left thigh, St. II–ІІІ сТ3N0M0. An en-bloc surgery (removal of the retroperitoneal tumor with mobilization of the left ureter, intraabdominal removal of the thigh part of the tumor of the left thigh from beneath the inguinal ligament) was performed after the standard preoperative preparation. The surgery went without complications. The wound healed primarily. The follow-up period of the patient was 16 months. Clinical laboratory examination did not show any local recurrences and distant metastases. Results. For retroperitoneal sarcoma, the goal of surgery is to achieve the complete resection of the tumor (R0). Partial removal (R2) tumor should be strongly avoided, as this has been demonstrated to have higher recurrence risk and a detrimental effect on oncologic outcomes. The tumor involvement of organs and structures does necessitate concomitant resection. Resection of one or more adjacent organs is carried out in 58–87% of all cases of primary RPS. Most commonly, ipsilateral nephrectomy and partial colectomy are also performed. In cases of hypothetical necessity of removing all adjacent organs, an extended or compartmental approach to resection is recommended. The main idea is to resect not only evidently affected organs but also surfaces to obtain circumferential «soft tissue margins». This approach is controversial but data from some sarcoma care centers in Italy and France indicate its effectiveness. Conclusions. Treating RPS in specialized centers of oncosurgery with surgical planning based on CT and MRI data is of vital importance, especially using assessment by related surgical specialists. In large RPS, achieving a classic R0 resection level is a challenge, even in a compartmental approach, therefore division of resections into R2 and R0/R1 is reasonable. The choice of approach determines success of the surgery due to the narrowness of the surgical field.

  • Open Access

    The effect of neoadjuvant chemotherapy on the structural and functional state of tumor cells in the secondary edematous form of breast cancer

    by O.P. Lukashova, О.м. Bilyy, V.S. Pakhomov, S.V. Shutov, О.V. Slobodianyuk, І.V. Lepekha, І.м. Teslenko

    Background. Secondary edematous form of breast cancer (SЕF BC) is the most aggressive type of BC that is characterized by rapid progression, high levels of metastasis, significant resistance to chemotherapy and radiotherapy. SЕF BC is not just a combination of cancer and local inflammation, but is a rare phenomenon in which the development of the tumor is primary. The processes of edema and inflammation occur because of lymph flow blockage by the formation of emboli from tumor cells (TC), which have elevated levels of E-cadherin, properties of polyploid cells and show signs of stem cells. Trimodal therapy methods are used for the treatment of SЕF BC, the main components of which are neoadjuvant systemic chemotherapy, surgery and adjuvant radiation therapy. However, the results of treatment remain insufficient, possibly due to the fact that the features of SЕF, the role of stem cells and inflammatory factors are not taken into account. Therefore, further research is needed in various fields of oncology, molecular biology, immunology, genetics, morphology, including electron microscopy, which is an important area for establishing the characteristics of both tumor cells and their environment. Purpose. Study of the neoadjuvant polychemotherapy influence on the structural and functional state of tumor cells of different molecular subtypes in the secondary edematous form of breast cancer. Materials and methods. Tumors of 29 patients with normal breast cancer and 32 patients with SЕF BC were studied. Receptors to estrogen (ER), progesterone (PR) and epidermal human growth factor 2 (HER2) were immunohistochemically determined before systemic neoadjuvant polychemotherapy (PCT). According to the receptor status, tumors were divided into 4 groups: 1 – triple negative («3-neg») tumors, 2 – HER2-positive («HER2») tumors, 3 – hormonally receptor («HP») tumors, 4 – tumorswith co-expression of hormonal receptors and HER2 («HR + HER2»). For polychemotherapy (PCT) the regimen (AСx4–Рx4) was used.The ultrastructure of the tumor cells (TC) was examined using standard electron microscopy methods. In all study groups, the frequency of cases with pronounced therapeutic pathomorphosis (PTPM) was determined, as well as the frequency of tumors with luminal and non-luminal symptoms after treatment. The obtained data were calculated using non-parametric methods with the software package for PC «Biostat» application and using a non-parametric criterion of the most plausible assessment of reliability for small selections (Pmp). Results. It was found that PCT in patients with conventional BC causes a pronounced therapeutic pathomorphosis (РТPM) of most tumors of the receptor groups «3-neg», «HER2» and «HR+HER2», compared with the group «HR», where no case of РTPM was observed. At SЕF BC the frequency of tumors with the pronounced pathomorphosis in groups with nonluminal subtypes and co-expression of receptors decreases, that for group «3-neg» is reliable. This indicates increased chemoresistance of triple negative tumors. In the group of hormone receptor tumors at SEF, this index increases significantly. Analysis of the ultrastructure of tumors of different molecular subtypes showed that most of the processes of damage and accompanying reactions to the action of PCT are identical for both forms of BC. Thus, in response to chemotherapy, different types of cell death: necrotic, dark cell, apoptotic; processes of cell nucleus damage: presence of dinuclear PCs, cells with micronuclei; disturbance of the microvessels structure: edema and condensation of the endothelial cells cytoplasm and their exfoliation; activation of phagocytosis and immune processes are observed. Only SЕF is characterized by the presence of TCs and emboli in capillaries, as well as a significantly increased frequency of giant polyploid tumor cells. It was also found that after PCT in patients with normal BC preserved tumor cells show mainly luminal signs (72.7–100%). However, in SЕF BC such reaction occurs only for hormone-receptor subtypes and the group with co-expression of receptors, whereas for tumors of three negative and HER2-positive subtypes the frequency of luminal signs is lower than in conventional BC and is 33.3%, p ≤ 0.05 and 66.7%, respectively. Conclusions. Peculiarities of SЕF BC in contrast to the usual form of BC are significantly reduced sensitivity of 3-negative cancer to chemotherapy and the tendency to chemoresistance of molecular subtypes with the presence of HER2; significant survival after PCT tumors with non-luminal cells characteristic in the group of 3-negative cancer, while in other receptor subtypes most tumors have luminal features; probably increased after chemotherapy the number of tumors with giant polyploid cells. It is possible that the features of SЕF BC are associated with the presence of polyploid TCs resistant to chemotherapy, and both inflammation and chemotherapy may play a role in stimulating their formation.